諾獎效應來了！Treg新公司「吸金」8000萬美元，艾伯維、賽諾菲、再生元支持

醫藥魔方Pro

10/29

在2025年諾貝爾生理學或醫學獎授予調節性T細胞（Treg）領域的三位科學家後，敏銳的風險資本迅速行動起來。10月28日，致力於胸腺靶向藥物開發的生物技術公司Zag Bio宣佈公司已完成8000萬美元孖展。Polaris Partners創立並孵化了Zag Bio，並與T1D Fund共同領投了近期的A輪孖展。參與此輪孖展的還包括AbbVie Ventures, Sanofi Ventures, ...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579967139"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579967139\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579967139?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-29 22:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2579967139","market":"us","top_or_hot":-1,"title":"諾獎效應來了！Treg新公司「吸金」8000萬美元，艾伯維、賽諾菲、再生元支持","media":"醫藥魔方Pro","content":"<div>\n<p>在2025年諾貝爾生理學或醫學獎授予調節性T細胞（Treg）領域的三位科學家後，敏銳的風險資本迅速行動起來。10月28日，致力於胸腺靶向藥物開發的生物技術公司Zag Bio宣佈公司已完成8000萬美元孖展。Polaris Partners創立並孵化了Zag Bio，並與T1D Fund共同領投了近期的A輪孖展。參與此輪孖展的還包括AbbVie Ventures, Sanofi Ventures, ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029235840a6d52b7f&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>諾獎效應來了！Treg新公司「吸金」8000萬美元，艾伯維、賽諾菲、再生元支持</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n諾獎效應來了！Treg新公司「吸金」8000萬美元，艾伯維、賽諾菲、再生元支持\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">醫藥魔方Pro</strong><span class=\"h-time small\">2025-10-29 22:22</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>在2025年諾貝爾生理學或醫學獎授予調節性T細胞（Treg）領域的三位科學家後，敏銳的風險資本迅速行動起來。10月28日，致力於胸腺靶向藥物開發的生物技術公司Zag Bio宣佈公司已完成8000萬美元孖展。Polaris Partners創立並孵化了Zag Bio，並與T1D Fund共同領投了近期的A輪孖展。參與此輪孖展的還包括AbbVie Ventures, Sanofi Ventures, ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029235840a6d52b7f&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029235840a6d52b7f&s=b\">醫藥魔方Pro</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1983299246.USD","symbol_name":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029235840a6d52b7f&s=b","article_id":"2579967139","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029235840a6d52b7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2579967139","pubTimestamp":1761747766,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"10月28日，致力於胸腺靶向藥物開發的生物技術公司Zag Bio宣佈公司已完成8000萬美元孖展。胸腺Treg在表觀遺傳上是穩定和持久的，有望實現具有持久影響的免疫重置。Zag Bio正在開發的ZAG-101是一種雙功能抗體，可將胰腺β細胞抗原遞送到胸腺，潛在適應症為1型糖尿病。具體機制來説，ZAG-101旨在擴大抗原特異性胸腺Treg，以保護β細胞免受破壞，並保持其在胰腺中產生胰島素的能力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","ABBV":"艾伯维公司","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4566":"资本集团","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","SG9999015978.USD":"利安颠覆性创新基金A","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H"},"translate_title":"The Nobel Prize effect is here! Treg's new company \"attracts gold\" of $80 million, backed by AbbVie, Sanofi, Regeneron","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9},"content_text":"在2025年諾貝爾生理學或醫學獎授予調節性T細胞（Treg）領域的三位科學家後，敏鋭的風險資本迅速行動起來。10月28日，致力於胸腺靶向藥物開發的生物技術公司Zag Bio宣佈公司已完成8000萬美元孖展。Polaris Partners創立並孵化了Zag Bio，並與T1D Fund共同領投了近期的A輪孖展。參與此輪孖展的還包括AbbVie Ventures, Sanofi Ventures, Regeneron Ventures等機構。Zag Bio發現了一種新的方法，能夠遞送耐受性抗原到胸腺中，以實現持久的抗原特異性中樞耐受，以治療自身免疫性疾病。Zag Bio設計了胸腺靶向雙功能抗體，將抗原遞送到胸腺，在那裏它參與人體對T細胞耐受的自然機制，擴增抗原特異性胸腺效應T細胞，同時消除抗原特異性效應T細胞（Teff）。之後，胸腺Treg遷移到病變組織，發揮廣泛的保護作用（簡言之，胸腺靶向雙功能抗體旨在重新訓練免疫系統，以阻止正在進行的自身免疫攻擊，同時促進健康組織的修復和恢復）。胸腺Treg在表觀遺傳上是穩定和持久的，有望實現具有持久影響的免疫重置。Zag Bio總部位於馬薩諸塞州，公司技術靈感來自其聯合創始人、哈佛醫學院免疫生物學教授Diane Mathis博士的工作，他的實驗室在免疫耐受領域做出了開創性的貢獻。最新孖展收益將用於推進Zag Bio針對1型糖尿病的先導項目進入臨牀，同時用於針對其他自身免疫性疾病的早期項目開發。Zag Bio正在開發的ZAG-101是一種雙功能抗體，可將胰腺β細胞抗原遞送到胸腺，潛在適應症為1型糖尿病。具體機制來説，ZAG-101旨在擴大抗原特異性胸腺Treg，以保護β細胞免受破壞，並保持其在胰腺中產生胰島素的能力。該公司已經在一系列臨牀前研究中對ZAG-101進行了評估，並正在啓動IND-enabling研究，以推動ZAG-101在2026年底進入臨牀開發。「儘管胸腺在中樞免疫耐受中起着不可或缺的作用，但所有類型的藥物都無法進入胸腺。通過Zag Bio的創新方法，我們希望開創一類新的胸腺靶向藥物，幫助1型糖尿病以及其他多種自身免疫性疾病患者。」Zag Bio首席執行官Jason Cole説道。參考資料：[1]https://zagbio.com/press-release/zag-bio-launches-with-80-million-financing-to-advance-thymus-targeted-medicines-for-autoimmune-diseases/[2]https://www.fiercebiotech.com/biotech/3-biopharma-heavies-contribute-80m-series-round-tregs-specialist-zag-bio推薦閲讀專訪清華大學石彥 | 中國first-in-class Treg藥物的破局與野望楊林：體內CAR-T爆發背後的幾點思考醫藥魔方Pro洞察全球生物醫藥前沿趨勢賦能中國源頭創新成果轉化媒體合作：15895423126Copyright © 2025 PHARMCUBE. All Rights Reserved.免責申明：本微信文章中的信息僅供一般參考之用，不可直接作為決策內容，醫藥魔方不對任何主體因使用本文內容而導致的任何損失承擔責任。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}